Education
About Us
Working with TipRanks
Follow Us
Clover Biopharmaceuticals Ltd. (HK:2197)
:2197
2197 Stock Chart & Stats
HK$2.37
>-HK$0.01(-2.10%)
At close: 4:00 PM EST
HK$2.37
>-HK$0.01(-2.10%)
Day’s Range― - ―
52-Week RangeHK$0.19 - HK$3.18
Previous CloseN/A
Volume1.38M
Average Volume (3M)29.82M
Market Cap
HK$2.86B
Enterprise ValueHK$2.14B
Total Cash (Recent Filing)HK$395.74M
Total Debt (Recent Filing)HK$13.05M
Price to Earnings (P/E)―
Beta2.56
Next Earnings
Mar 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding1,298,037,500
10 Day Avg. Volume32,349,599
30 Day Avg. Volume29,824,166
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.17
Price to Sales (P/S)7.39
P/FCF Ratio-0.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Protein Subunit TechnologyA reusable protein subunit vaccine platform provides a durable competitive advantage: it can be adapted to new antigens, supports scalable manufacturing, and often has favorable safety profiles. Over months this platform boosts pipeline flexibility and licensing potential for sustained R&D efficiency.
Partnerships And Government ContractsEstablished partnerships and government/institutional contracts provide non-dilutive funding, demand visibility, and distribution channels. Structurally, these relationships reduce commercialization risk, support clinical development costs, and improve market access over a multi-month horizon.
Top-line Growth TrendHigh reported revenue growth indicates accelerating commercial traction or contract revenues. Sustained top-line expansion, if maintained, enhances scale economies, supports future margin recovery, and provides operational runway to progress clinical programs without immediate reliance on capital markets.
Bears Say
Persistent Operating LossesOngoing net losses erode retained capital and make internal funding of trials and commercialization difficult. Persisting deficits over months force reliance on external financing, which can be dilutive or costly, constraining long-term investment and strategic flexibility.
Negative Stockholders' Equity / High LeverageNegative equity and high leverage reduce financial resilience and limit borrowing capacity. Over a medium-term horizon this condition heightens counterparty and regulatory risk, can impair partner confidence, and may necessitate restructuring or equity raises under unfavorable terms.
Negative Operating Cash Flow And Shrinking CashConsistent negative operating cash flow and declining cash reserves constrain the company's ability to fund trials, scale manufacturing, or commercialize products organically. This structural cash burn raises the probability of fundraising, dilution, or project delays within months.
Clover Biopharmaceuticals Ltd. News
2197 FAQ
What was Clover Biopharmaceuticals Ltd.’s price range in the past 12 months?
Clover Biopharmaceuticals Ltd. lowest stock price was HK$0.18 and its highest was HK$3.18 in the past 12 months.
What is Clover Biopharmaceuticals Ltd.’s market cap?
Clover Biopharmaceuticals Ltd.’s market cap is HK$2.86B.
When is Clover Biopharmaceuticals Ltd.’s upcoming earnings report date?
Clover Biopharmaceuticals Ltd.’s upcoming earnings report date is Mar 31, 2026 which is in 36 days.
How were Clover Biopharmaceuticals Ltd.’s earnings last quarter?
Clover Biopharmaceuticals Ltd. released its earnings results on Aug 27, 2025. The company reported -HK$0.086 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.086.
Is Clover Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Clover Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Clover Biopharmaceuticals Ltd. pay dividends?
Clover Biopharmaceuticals Ltd. does not currently pay dividends.
What is Clover Biopharmaceuticals Ltd.’s EPS estimate?
Clover Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clover Biopharmaceuticals Ltd. have?
Clover Biopharmaceuticals Ltd. has 1,298,037,500 shares outstanding.
What happened to Clover Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Clover Biopharmaceuticals Ltd. reported an EPS of -HK$0.086 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -17.391%.
Which hedge fund is a major shareholder of Clover Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in HK:2197
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clover Biopharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
589.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-66.29%
Trailing 12-Months
Company Description
Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.
Technical Analysis
Kintor Pharmaceutical Ltd
―
HBM Holdings Ltd.
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
Sirnaomics Ltd.
―
Transcenta Holding Limited
―